c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells

Hayashi,Keitaro; Jutabha,Promsuk; Endou,Hitoshi; Anzai,Naohiko

doi:10.3892/or.2012.1878

c-Myc is crucial for the expression of LAT1 in MIA Paca-2 human pancreatic cancer cells

Authors:
- Keitaro Hayashi
- Promsuk Jutabha
- Hitoshi Endou
- Naohiko Anzai
View Affiliations

Affiliations: Department of Pharmacology and Toxicology, Dokkyo Medical University School of Medicine, 880 Kitakobayashi, Mibu, Tochigi 321-0293, Japan, J-Pharma Co., Ltd., 2-16-8 Shinjuku, Shinjuku-ku, Tokyo 160-0022, Japan
Published online on: June 20, 2012 https://doi.org/10.3892/or.2012.1878
Pages: 862-866

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor cells take up a massive amount of nutrition compared to normal cells for increased metabolism. Therefore, special transporters for organic materials are required to satisfy the powerful consumption of nutrition in tumor cells. L-type amino acid transporter 1 (LAT1) incorporates large neutral amino acids, most of which are also categorized as essential amino acids, into cells in a Na+-independent manner. Because of its high expression levels in a variety of cancer cells, it is speculated that LAT1 functions as a key transporter for highly effective delivery of essential amino acids into cancer cells. In this regard, LAT1 inhibitor is expected to have clinical benefit for cancer therapy. However, the molecular mechanism of enrichment of LAT1 in cancer cells remains poorly understood. Here, we show that a proto-oncogene, c-Myc, is a critical positive regulator of LAT1 expression in MIA Paca-2 human pancreatic cancer cells. The uptake of leucine, a representative neutral amino acid, was strictly dependent on LAT1 in MIA Paca-2 cells, and siRNA-mediated knockdown of LAT1 inhibited cell proliferation. Diminished c-Myc expression with siRNA resulted in severe reduction of LAT1 protein levels as well as mRNA levels, which, in turn, led to a significant defect of leucine incorporation. The LAT1 promoter has a canonical c-Myc binding sequence and overexpression of c-Myc increased LAT1 promoter activity, whereas mutation of c-Myc binding site diminished this effect. Our results suggest biological significance of LAT1 in tumor growth and molecular machinery that could explain why LAT1 is preferentially expressed in cancer cells.

View Figures

View References

1	DeBerardinis RJ, Lum JJ, Hatzivassiliou G and Thompson CB: The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7:11–20. 2008. View Article : Google Scholar : PubMed/NCBI
2	Warburg O: On the origin of cancer cells. Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
3	Airley RE and Mobasheri A: Hypoxic regulation of glucose transport, anaerobic metabolism and angiogenesis in cancer: novel pathways and targets for anticancer therapeutics. Chemotherapy. 53:233–256. 2007. View Article : Google Scholar : PubMed/NCBI
4	Macheda ML, Rogers S and Best JD: Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol. 202:654–662. 2005. View Article : Google Scholar : PubMed/NCBI
5	Witte D, Ali N, Carlson N and Younes M: Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res. 22:2555–2557. 2002.PubMed/NCBI
6	Li R, Younes M, Frolov A, Wheeler TM, Scardino P, Ohori M and Ayala G: Expression of neutral amino acid transporter ASCT2 in human prostate. Anticancer Res. 23:3413–3418. 2003.PubMed/NCBI
7	Levine AJ and Puzio-Kuter AM: The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science. 330:1340–1344. 2010. View Article : Google Scholar : PubMed/NCBI
8	Ganapathy V, Thangaraju M and Prasad PD: Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 121:29–40. 2009. View Article : Google Scholar : PubMed/NCBI
9	Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E and Endou H: Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 273:23629–23632. 1998. View Article : Google Scholar : PubMed/NCBI
10	Yanagida O, Kanai Y, Chairoungdua A, et al: Human L-type amino acid transporter 1 (LAT1): characterization of function and expression in tumor cell lines. Biochim Biophys Acta. 1514:291–302. 2001. View Article : Google Scholar : PubMed/NCBI
11	Oda K, Hosoda N, Endo H, et al: L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci. 101:173–179. 2010. View Article : Google Scholar : PubMed/NCBI
12	Ichinoe M, Mikami T, Yoshida T, et al: High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: comparison with non-cancerous lesions. Pathol Int. 61:281–289. 2011. View Article : Google Scholar : PubMed/NCBI
13	Nii T, Segawa H, Taketani Y, et al: Molecular events involved in up-regulating human Na⁺-independent neutral amino acid transporter LAT1 during T-cell activation. Biochem J. 358:693–604. 2001.PubMed/NCBI
14	Blackwell TK, Kretzner L, Blackwood EM, Eisenman RN and Weintraub H: Sequence-specific DNA binding by the c-Myc protein. Science. 250:1149–1151. 1990. View Article : Google Scholar : PubMed/NCBI
15	Alex R, Sözeri O, Meyer S and Dildrop R: Determination of the DNA sequence recognized by the bHLH-zip domain of the N-Myc protein. Nucleic Acids Res. 20:2257–2263. 1992. View Article : Google Scholar : PubMed/NCBI
16	Sakata T, Ferdous G, Tsuruta T, et al: L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int. 59:7–18. 2009. View Article : Google Scholar : PubMed/NCBI
17	Kaira K, Oriuchi N, Imai H, et al: Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung. Cancer Sci. 100:248–254. 2009. View Article : Google Scholar
18	Kaji M, Kabir-Salmani M, Anzai N, et al: Properties of L-type amino acid transporter 1 in epidermal ovarian cancer. Int J Gynecol Cancer. 20:329–336. 2010. View Article : Google Scholar : PubMed/NCBI
19	Bouchard C, Thieke K, Maier A, et al: Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 18:5321–5333. 1999. View Article : Google Scholar : PubMed/NCBI
20	Bouchard C, Dittrich O, Kiermaier A, Dohmann K, Menkel A, Eilers M and Lüscher B: Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. 15:2042–2047. 2001. View Article : Google Scholar : PubMed/NCBI
21	Menssen A and Hermeking H: Characterization of the c-Myc-regulated transcriptome by SAGE: identification and analysis of c-Myc target genes. Proc Natl Acad Sci USA. 99:6274–6279. 2002. View Article : Google Scholar : PubMed/NCBI
22	Kim JW, Zeller KI, Wang Y, Jegga AG, Aronow BJ, O’Donnell KA and Dang CV: Evaluation of myc E-box phylogenetic footprints in glycolytic genes by chromatin immunoprecipitation assays. Mol Cell Biol. 24:5923–5936. 2004. View Article : Google Scholar : PubMed/NCBI
23	Osthus RC, Shim H, Kim S, et al: Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem. 275:21797–21800. 2000. View Article : Google Scholar : PubMed/NCBI
24	O’Donnell KA, Wentzel EA, Zeller KI, Dang CV and Mendell JT: c-Myc-regulated microRNAs modulate E2F1 expression. Nature. 435:839–843. 2005.PubMed/NCBI
25	Frank SR, Schroeder M, Fernandez P, Taubert S and Amati B: Binding of c-Myc to chromatin mediates mitogen-induced acetylation of histone H4 and gene activation. Genes Dev. 15:2069–2082. 2001. View Article : Google Scholar : PubMed/NCBI
26	Frank SR, Parisi T, Taubert S, et al: Myc recruits the TIP60 histone acetyltransferase complex to chromatin. EMBO Rep. 4:575–580. 2003. View Article : Google Scholar : PubMed/NCBI